Emanuel Ezekiel J, Wood Anne, Fleischman Alan, Bowen Angela, Getz Kenneth A, Grady Christine, Levine Carol, Hammerschmidt Dale E, Faden Ruth, Eckenwiler Lisa, Muse Carianne Tucker, Sugarman Jeremy
Department of Clinical Bioethics, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892-1156, USA.
Ann Intern Med. 2004 Aug 17;141(4):282-91. doi: 10.7326/0003-4819-141-4-200408170-00008.
The oversight of research involving human participants is widely believed to be inadequate. The U.S. Congress, national commissions, the Department of Health and Human Services, the Institute of Medicine, numerous professional societies, and others are proposing remedies based on the assumption that the main problems are researchers' conflict of interest, lack of institutional review board (IRB) resources, and the volume and complexity of clinical research. Developing appropriate reform proposals requires carefully delineating the problems of the current system to know what reforms are needed. To stimulate a more informed and meaningful debate, we delineate 15 current problems into 3 broad categories. First, structural problems encompass 8 specific problems related to the way the research oversight system is organized. Second, procedural problems constitute 5 specific problems related to the operations of IRB review. Finally, performance assessment problems include 2 problems related to absence of systematic assessment of the outcomes of the oversight system. We critically assess proposed reforms, such as accreditation and central IRBs, according to how well they address these 15 problems. None of the reforms addresses all 15 problems. Indeed, most focus on the procedural problems, failing to address either the structure or the performance assessment problems. Finally, on the basis of the delineation of problems, we outline components of a more effective reform proposal, including bringing all research under federal oversight, a permanent advisory committee to address recurrent ethical issues in clinical research, mandatory single-time review for multicenter research protocols, additional financial support for IRB functions, and a standardized system for collecting and disseminating data on both adverse events and the performance assessment of IRBs.
人们普遍认为,对涉及人类受试者的研究的监督是不够的。美国国会、国家委员会、卫生与公众服务部、医学研究所、众多专业协会以及其他机构都在提出补救措施,其依据的假设是主要问题在于研究人员的利益冲突、机构审查委员会(IRB)资源不足以及临床研究的数量和复杂性。制定适当的改革提案需要仔细界定当前系统的问题,以便了解需要进行哪些改革。为了激发更明智、更有意义的辩论,我们将当前的15个问题划分为3大类。首先,结构性问题包括与研究监督系统的组织方式相关的8个具体问题。其次,程序性问题构成了与IRB审查操作相关的5个具体问题。最后,绩效评估问题包括与缺乏对监督系统结果的系统评估相关的2个问题。我们根据这些改革措施对这15个问题的解决程度,对诸如认证和中央IRB等提议的改革进行了批判性评估。没有一项改革能解决所有15个问题。事实上,大多数改革都集中在程序性问题上,未能解决结构或绩效评估问题。最后,在对问题进行界定的基础上,我们概述了一个更有效的改革提案的组成部分,包括将所有研究纳入联邦监督之下、设立一个常设咨询委员会以处理临床研究中反复出现的伦理问题、对多中心研究方案进行强制性一次性审查、为IRB的职能提供额外的财政支持,以及建立一个用于收集和传播不良事件数据以及IRB绩效评估数据的标准化系统。